Table 2.
Associations of clinical characteristics with QTc length in combined SLE/RA cohort
| Clinical covariates | Univariable model QTc (continuous) | Multivariable model QTc (continuous)a | ||
|---|---|---|---|---|
| Β | p | Β | p | |
| Age | 0.38 | < 0.005 | 0.21 | 0.033 |
| Sex | 0.31 | 0.92 | ---------- | ---------- |
| Race (white vs non-white) | 6.2 | < 0.05 | − 0.29 | 0.92 |
| Disease duration (square root) | − 0.1 | 0.86 | ---------- | ---------- |
| Current HCQ use | − 7.8 | < 0.005 | 0.22 | 0.95 |
| Current prednisone use | − 9.8 | < 0.005 | − 8.27 | 0.018 |
| Current biologic use | 0.45 | 0.87 | ---------- | ---------- |
| Hypertension | 3.6 | 0.11 | 3.01 | 0.29 |
| Current smoking | 10.6 | < 0.05 | 10.2 | 0.033 |
| Diabetes | 8.9 | < 0.05 | 0.69 | 0.88 |
| Current statin use | 2.7 | 0.38 | ---------- | ---------- |
| Current aspirin use | − 7.1 | < 0.05 | − 3.9 | 0.22 |
| Any QTc meds | − 1.4 | 0.56 | ---------- | ---------- |
| Antidepressants | 7.1 | < 0.05 | ---------- | ---------- |
| Antipsychotics | − 1.6 | 0.80 | ---------- | ---------- |
| Antiarrhythmics | 5.4 | 0.49 | ---------- | ---------- |
| Muscle relaxants | 9.6 | 0.12 | ---------- | ---------- |
| Antimicrobials | − 0.2 | 0.96 | − 2.4 | 0.46 |
| Antiemetics | 1.8 | 0.63 | ---------- | ---------- |
| Anticonvulsants | 7.9 | 0.21 | ---------- | ---------- |
| Tacrolimus | − 0.5 | 0.92 | ---------- | ---------- |
| Ejection fraction % | 0.05 | 0.77 | ---------- | ---------- |
| Ejection fraction ≥ 55% | − 3.2 | 0.47 | ---------- | ---------- |
| Prob > F | ---------- | 0.0001 | ||
Abbreviations: HCQ hydroxychloroquine, QtC QT corrected interval
aFinal imputed data